Clinical Trial Update: A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating ibrutinib in combination with obinutuzumab for relapsed or refractory Chronic Lymphocytic Leukemia. The trial is currently ACTIVE_NOT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Gazyva (Obinutuzumab)
• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING